Recently, Celgene (CELG) and its partner Agios Pharmaceuticals (AGIO) announced that the FDA has approved enasidenib (AG-221) for treating patients with acute myeloid leukemia (AML). I wouldn't say there is a risk right now, but Novartis just recently received approval for its AML drug Rydapt.AML approval approved Celgene drug FDA genetic mutation market patient treatment
Bioverativ (BIVV) is a recent spin-off from Biogen Idec (BIIB), which focuses on rare blood diseases, primarily hemophilia.
Bioverativ is a global biotechnology company focused on the discovery, research, development and commercialization of therapies for the treatment of hemophilia and other blood disorders.Biogen Bioverativ disease hemophilia market patient product Revenue sales treatment
While the biggest companies are often likened to large ships that move in long sweeping paths rather than at sharp angles like smaller, more agile vessels, sometimes even the biggest battleships can advance with startling speed. Micron has been able to capitalize on that as a result of a stronger DRAM pricing environment, a better product mix, and lower cost-per-bit in both DRAM and NAND; and a large part of that is because more smartphone manufacturers are adding more DRAM to their devices.chipmaker DRAM earnings investment Micron NASDAQ Netflix NVIDIA quarter stock
If you're in the market for a new role, there's a good chance you're hoping for a permanent gig.
Think about it: It's in a company's best interest to hire internally when new positions open, because there's less training and risk involved.employer employment job opportunity permanent position re role temporary worker
Apple (NASDAQ: AAPL) reported its financial results on Aug. 1 and released its accompanying quarterly filing (form 10-Q) just a day later.
In that filing, Apple gave quite a lot of detail beyond what the earnings press release provided and served to further supplement the commentary that management provided on the earnings call.Apple filing fiscal Greater China growth iPhone quarter region Revenue year
In this Market Foolery podcast segment, host Chris Hill and Motley Fool One 's Bill Mann consider how much worse Teva Pharmaceutical Industries (NYSE: TEVA) looks presently, after a second quarter report that featured weak sales, low profits, a 75% dividend cut, and -- to top it off -- a guidance reduction. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.cut debt dividend Hill lower Mann Motley Fool pharmaceutical stock Teva
South Korea has become a focal point for geopolitical tension, because its neighbor to the north has made increasingly provocative moves with its nascent arsenal of missiles. South Korea plays a strong role in the economy of the Asia-Pacific region, and its manufacturing capacity has made it a key source of electronics and other important goods throughout the global economy.closed end ETF fund investors Korea Korean stock market position South stock
Information technology services provider Gartner, Inc. As a result, information technology has become critical for all firms to support higher productivity, improve performance metrics and protect the enterprise from cyber-security threats.addition earnings estimate Gartner growth market quarter Revenue services Zacks
Dow ChemicalDOW and DuPont DD said that they have received all required regulatory approvals and clearances for their planned mega-merger. Moreover, shares of the new combined entity, "DowDuPont" will start trading on the NYSE under the ticker symbol "DWDP" on Sep 1.companies consumer Dow earnings growth market merger quarter shares Zacks
Big 5 Sporting Goods Corp.BGFV has plunged 14.6% since it came out with second-quarter 2017 results on Aug 1.
Big 5 Sporting reported adjusted earnings of 13 cents per share, up 18.2% from 11 cents earned in the prior-year quarter.Big Sporting cents comps earnings prior year quarter remain results sales Zacks
The earnings season is at its tail end with about 420 S&P 500 companies having reported results till Aug 4. Reconfirming broad-based expectations of better-than- expected results, total earnings of these 420 firms (accounting for 86.7% of the index's total market capitalization) are up 11.6% year over year on 5.6% higher revenues, with 74.3% beating earnings estimates and 68.3% surpassing top-line expectations.bell business earnings growth higher quarter report results services stocks
Despite recent negative news from gun manufacturers, the future for the industry remains bright. However, 2017 is clearly on track to be the second best gun sales year on record (despite the pulled forward sales in 2016), beating all of the Obama years except for 2016.AOBC companies continue demand earnings gun long term market RGR sales
NEW DELHI: The domestic equity market witnessed rangebound trade all through Monday, and NSE benchmark Nifty50 could not move beyond a 45-point range before eventually settling the day at around its five-day exponential moving average (EMA) of 10,056.The index made a small bearish candle on the daily chart and momentum indicator MACD saw a negative crossover, indicating that the index may stay rangebound in the coming sessions.The index opened the day at 10,074 and hit a high and low of 10,088 and 10,046, respectively. This suggests we will see more consolidation and the 10,114-10,150 zone remain the immediate resistance for the index,” said Milan Vaishnav, CMT, Consultant Technical Analyst at Gemstone Equity Research & Advisory Services.Vaishnav does not expect any meaningful and sustainable break out until the Nifty moves beyond these said resistance levels.“We can expect rangebound trade with a downward bias for a few more days,” he said.day EMA equity eventually index market Nifty50 NSE rangebound trade